Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Laura R. Prakash

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1846-2361; OpenAlex author ID A5000811595, A5112698737, A5113274743. Sources: OpenAlex.

Their work

Papers
61 (first author 13, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
206
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 5 papers · 2020: 7 papers · 2021: 10 papers · 2022: 6 papers · 2023: 7 papers · 2024: 7 papers · 2025: 2 papers · 2026: 8 papers

Papers 50 of 61

  1. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  2. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  3. Clinicopathologic Characteristics of Brain Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000002470↗
  4. Exercise Modulates Microbial Metabolites and Induces Stromal Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5143↗
  5. Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Do… Co-author DOI 10.1200/op-25-01431↗
  6. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  7. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  8. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  9. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  10. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006269↗
  11. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00464-024-11022-3↗
  12. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surg… Co-author DOI 10.1093/bjs/znae033↗
  13. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  14. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  15. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRIN… Co-author DOI 10.1245/s10434-023-14680-0↗
  16. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and … Last author DOI 10.1245/s10434-023-14815-3↗
  17. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  18. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. First author DOI 10.1007/s11605-022-05534-3↗
  19. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  20. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  21. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  22. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  23. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  24. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  25. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Co-author DOI 10.1002/jso.26989↗
  26. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  27. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. First author DOI 10.1016/j.suronc.2021.101673↗
  28. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  29. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  30. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  31. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  32. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. First author DOI 10.1002/jso.26650↗
  33. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Co-author DOI 10.1016/j.adro.2021.100763↗
  34. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.003↗
  35. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Co-author DOI 10.1016/j.pan.2021.03.018↗
  36. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Co-author DOI 10.1016/j.pan.2021.08.006↗
  37. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. First author DOI 10.1097/sla.0000000000003442↗
  38. The Role of Home-Based Exercise in Maintaining Skeletal Muscle During Preoperative Pancreatic Cancer Treatment. Co-author DOI 10.1177/1534735420986615↗
  39. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09013-4↗
  40. Factors Influencing Exercise Following Pancreatic Tumor Resection. Co-author DOI 10.1245/s10434-020-09062-9↗
  41. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. First author DOI 10.1001/jamasurg.2020.2286↗
  42. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. Co-author DOI 10.1007/s11605-019-04126-y↗
  43. Defining and Treating Borderline Resectable Pancreatic Cancer. First author DOI 10.1007/s11864-020-00769-1↗
  44. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000003763↗
  45. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  46. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. First author DOI 10.1245/s10434-020-08427-4↗
  47. Response to Preoperative Therapy in Localized Pancreatic Cancer. First author DOI 10.3389/fonc.2020.00516↗
  48. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. First author DOI 10.1016/j.hpb.2018.10.009↗
  49. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimi… First author DOI 10.1016/j.hpb.2018.10.018↗
  50. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIR… Co-author DOI 10.1097/mpa.0000000000001345↗

Closest collaborators

The 25 strongest of 206 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 61 shared papers, 2015–2026 · strength 8.58
  2. Ching-Wei David Tzeng · 42 shared papers, 2017–2026 · strength 6.19
  3. Michael P. Kim · 36 shared papers, 2016–2026 · strength 4.68
  4. Jeffrey E. Lee · 35 shared papers, 2015–2026 · strength 4.21
  5. Naruhiko Ikoma · 22 shared papers, 2020–2026 · strength 3.51
  6. Robert A. Wolff · 23 shared papers, 2015–2026 · strength 2.66
  7. Eugene Jon Koay · 20 shared papers, 2016–2025 · strength 2.17
  8. Huamin Wang · 19 shared papers, 2015–2026 · strength 2.03
  9. Marc G. Besselink · 10 shared papers, 2022–2026 · strength 1.84
  10. Anirban Maitra · 17 shared papers, 2015–2026 · strength 1.83
  11. Amer H. Zureikat · 9 shared papers, 2022–2026 · strength 1.71
  12. Bas Groot Koerkamp · 9 shared papers, 2022–2026 · strength 1.71
  13. Alice Chia-Chi Wei · 9 shared papers, 2022–2026 · strength 1.71
  14. Rebecca Anne Snyder · 8 shared papers, 2016–2026 · strength 1.66
  15. Quisette P. Janssen · 8 shared papers, 2022–2026 · strength 1.45
  16. Hua Wang · 8 shared papers, 2015–2026 · strength 1.17
  17. Dan Zhao · 6 shared papers, 2023–2026 · strength 1.16
  18. Eileen Mary O'Reilly · 6 shared papers, 2022–2026 · strength 1.15
  19. Milind M. Javle · 13 shared papers, 2016–2023 · strength 1.06
  20. Gauri Rajani Varadhachary · 14 shared papers, 2015–2021 · strength 1.05
  21. David R. Fogelman · 14 shared papers, 2016–2021 · strength 1.03
  22. Deesje Doppenberg · 6 shared papers, 2022–2024 · strength 1.00
  23. Shubham Pant · 8 shared papers, 2020–2025 · strength 0.98
  24. Rutger T. Theijse · 5 shared papers, 2024–2025 · strength 0.93
  25. Giampaolo Perri · 7 shared papers, 2020–2022 · strength 0.89

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.